The 12 kDa FK506-binding protein FKBP12 is a cis-trans peptidyl-prolyl isomerase that binds the macrolides FK506 and rapamycin. We have examined the role of the binding pocket residues of FKBP12 in protein-ligand interactions by making conservative substitutions of 12 of these residues by site-directed mutagenesis. For each mutant FKBP12, we measured the affinity for FK506 and rapamycin and the catalytic efficiency in the cis-trans peptidyl-prolyl isomerase reaction. The mutation of Trp59 or Phe99 generates an FKBP12 with a significantly lower affinity for FK506 than wild-type protein. Tyr26 and Tyr82 mutants are enzymatically active, demonstrating that hydrogen bonding by these residues is not required for catalysis of the cistrans peptidyl-prolyl isomerase reaction, although these mutations alter the substrate specificity of the enzyme. We conclude that hydrophobic interactions in the active site dominate in the stabilization of FKBP12 binding to macrolide ligands and to the twisted-amide peptidyl-prolyl substrate intermediate.
FKBP12 to membrane receptors, but impart affinities to FKBP12 for binding to intracellular enzymes. In T-lymphocytes, the binding of FK506 to FKBP12 interrupts cytosolic signaling events, resulting in the inhibition of early gene expression induced by ionophores, phorbol esters or anti-Tcell receptor antibodies (Sigal and Dumont, 1992) . This signal transduction pathway is inhibited when the FKBP12-FK506 complex binds to calcineurin (K\ 6 nM; Aldape et al., 1992) , a Ca 2+ -activated, calmodulin-dependent serine/threonine protein phosphatase (Liu et al, 1991) . We have described previously the effects of surface residue mutations on the affinity of FKBP12-FK506 for calcineurin (Aldape et al, 1992; Futer et al, 1995) . FKBP12 also binds rapamycin with high affinity {K x 0.2 nM). This macrolide exerts an immunosuppressive effect by blocking T-cell responses to interleukin-2 receptor signaling, a late event in T-cell activation (Sigal and Dumont, 1992) . The target for the FKBP12-rapamycin complex has been identified as TOR2 in yeast (Kunz et al, 1993) and FRAP (or RAFT1) in mammalian cells (Brown et al, 1994; Sabatini et al, 1994) , proteins with sequence homology to rP 3 kinase. Formation of the ternary FKBP12-rapamycin-TOR2 complex arrests the cell cycle.
FKBP 12 also catalyzes the cis-trans isomerization of the prolyl amide bonds of polypeptide substrates (the peptidylprolyl isomerase or PPIase reaction; Harding et al, 1989; Siekerka et al, 1989) . The substrate specificity for FKBP12 catalysis of the PPIase reaction has been reported (Harrison and Stein, 1990a) , and the mechanism of this reaction has been studied by steady-state kinetic methods (Harrison and Stein, 1990b; Kofron et al, 1991; Park et al, 1992) . The PPIase activity of FKBP12 may be relevant to its association Introduction FKBP12, a 12 kDa multifunctional FK506-binding protein, is an intracellular receptor for the immunosuppressant macrolides FK506 (tacrolimus; Figure 1 ) and rapamycin (sirolimus) (Armistead and Harding, 1993; Galat, 1993; Fruman et al, 1994) . FKBP12 was the first member of the multi-gene FKBP family to be identified (DiLella and Craig, 1991; Peartie et al, 1992 Peartie et al, , 1994 Hendrickson et al, 1993) . The structure and function of FKBP 12 has been investigated intensely since it was identified in thymus and T-cell extracts (Harding et al, 1989; Siekerka et al, 1989) . In the absence of macrolide ligands, FKBP12 can associate with the ryanodine Ca 2+ channel (Jayaraman et al, 1992) and modulate its stability and conductance (Mayerleitner et al, 1994) . FKBP12 also appears to modulate the activity of the phosphatidyl inositol receptor (TP 3 R) Ca 2+ channel (Cameron et al, 1995) . Upon binding of FK506 or rapamycin, associations of FKBP 12 with these transmembrane proteins are disrupted, thereby destabilizing the receptors and altering their activity. . The side chains of residues which have been mutated in this investigation are shown in stick format. Phe residues are displayed in purple, Tyr residues in yellow; Trp59 is grey, Asp37 is red, His87 is dark blue and Ile90 is orange. FK506 is shown in green. The exposed face of FK506, which does not interact with FKBP12, has been removed for clarity. The C o trace of FKBP12 is shown as a blue ribbon. Key hydrogen bonding interactions between FK506 and FKBP12 are shown as white dotted lines. Coordinates of the complex used are from Wilson et al. (1995) . (B) Stereoview of the complex of FKBP12 with an Ac-Leu-Pro-Phe-NMe twisted-amide substrate intermediate. The Leu-Pro amide bond is in the high-energy twisted conformation. The conformation is representative of those found in a 500 ps MD simulation (Orozco et al., 1993) . The side chains of residues which have been studied by mutagenesis are shown in stick format, with the same color scheme as in (A). The substrate is shown in green. A critical water molecule which forms a bndging hydrogen bond between the twisted amide carbonyl and Tyr82 is shown in a light blue ball-and-stick format. The hydrogen bonds made by this water molecule are shown as white dotted lines. The Pj Leu side chain is pointing towards the lipophilic pocket composed of residues Phe36, His87, Ile90, Ile91, Ile97 and Phe99. Coordinates of the unliganded FKBP12 from Wilson el al. (1995) were used to construct this model.
with the ryanodine receptor and the binding and modulation of IP3R (Cameron et al., 1995) . Three-dimensional structures have been reported for FKBP12 (Moore et al., 1991; Wilson et al., 1995) , for the binary complexes of FKBP12 with FK506 and rapamycin (Van Duyne et al., 1991 , 1993 Wilson et al, 1995) , and for the ternary complex of FKBP12-FK506-calcineurin (Griffith et al, 1995) . Both hydrophobic interactions and hydrogen bonds from macrolide ligands to protein side-chain and backbone heteroatoms stabilize these complexes ( Figure 2A and Table I ). Nevertheless, structural information alone is insufficient for the determination of the relative or absolute energetic contributions of each of the hydrophobic and hydrogen bonding interactions to the stability of these complexes. The binding and catalytic constants of a set of FKBP12 mutants, however, in concert with the structural data, can aid in the understanding of selected FKBP12 residue interactions with its protein and macrolide ligands. Here we report a mutational analysis of the active site of FKBP12 with respect to the ligand-binding affinity and catalytic efficiency of the PPIase reaction. We FKBP12 residues that interact with FK506 and their lnterprotein contacts (Van Duyne et al., 1991 , 1993 Wilson et al., 1995) Hydrophobic pocket-forming residues are Tyr26, Phe36, Phe46, Val55, Ile56, Trp59, His87, Ile90, Ile91, Leu97 and Phe99. demonstrate the differential effects of conservative active-site mutations on the binding interactions with macrolide ligands and PPIase substrates. 
Materials and methods

Materials and chemicals
Bacterial strains and plasmids
For site-directed mutagenesis, the durung' Escherichia coli strain CJ236 was used for uracil enrichment of single-strand DNA and the Nova Blue strain (NovaGene) was used for the selection of heteroduplex DNA after extension-ligation reactions. The E.coli strains used for the expression of human FKBP12 mutants (Park et al., 1992) were XA90, obtained from G.Verdine (Harvard University, Cambridge, MA), and CAG626 (a Ion' strain on an SCI22 background), obtained from C.Gross (University of Wisconsin, Madison, WI). A pKEN2 phagemid (G.Verdine) was used for site-directed mutagenesis. FKBP12 proteins were expressed in this vector, as described previously (Park et al., 1992) . Mutagenesis Site-directed mutagenesis of FKBP12 was performed as described previously (Park et al, 1992) . A 431 bp EcoKl fragment encoding human FKBP12 cDNA was ligated into phagemid pKEN2. All oligonucleotide-directed mutagenesis was performed on the pKEN2-FKBP12 constructs using uracil enrichment of single-strand DNA by the modification of Kunkel (Kunkel, 1985; Kunkel et al., 1987) of the method described originally for M13 mutagenesis (Zoller and Smith, 1982, 1983) . A two-primer mutagenesis was performed to construct the double mutants. All mutants were sequenced using the dideoxy method (Sanger et al., 1977) from the promoter through the region surrounding the mutagenesis site, and most were sequenced in their entirety in die coding region.
Mutagenesis primers were synthesized in the (+) coding orientation. Oligonucleotides were synthesized on an Applied Biosystems 38OA DNA synthesizer and purified by electrophoresis in polyacrylamide-urea slab gels, followed by extraction from the acrylamide gel by ammonium acetate and purification on a Sep-Pak cartridge. The following primers were used to generate FKBP12 mutants: for Y26F, 5'-GTG-GTGCACTTCACCGGGATG-3'; for F36L, 5'-AAGATGGA-AAGAAACTGGATTCCTCCCGG-3'; for D37V, 5'-GGAAA-GAAATTTGTATCCTCCCGTGA-3'; for R42I, 5'-CCTCC-CGTGACATCAACAAGCCCTTT-3'; for F46L, 5'-GTAAC-AAGCCCCTGAAGTTTATGCTAG-3'; for F48L, 5'-AAGC-CCTTTAAGCTGATGCTAGGCAAG-3'; for W59L, 5'-GTG-ATCCGAGGCCTGGAAGAAGGGGTT-3'; for W59A, 5'-G-TGATCCGAGGCGCTGAAGAAGGGGTT-3'; for Y80F, 5'-TATATCTCCAGATTTCGCCTATGGTGC-3'; for Y82F, 5'-CCAGATTATGCCTTCGGTGCCACTGG-3'; for H87V, 5'-GTGCCACTGGGGTACCAGGCATCAT-3'; and for F99L, 5'-CCACTCTCGTCCTGGATGTGGAGCTT-3'. The FKBP12 Y26F/Y82F double mutant was made by two-primer mutagenesis with the primers designed for the individual mutants. The construction of the D37V, H87L and I90A mutants has been described previously (Aldape et al., 1992; Futer et al, 1995) . 
Expression and purification of proteins
Mutant duplex DNA was transformed into XA90 cells for expression and plated on LB plates containing 100 ng/ml ampicillin. Overnight cultures were started from multiple colonies and grown at 37°C in LB-ampicillin medium. For expression, cultures were grown at 37°C in 2 1 shake flasks or in a 10 1 fermentor (Biostat ED, B.Braun). Culture medium (LB-ampicillin) was inoculated at a density of 1:100 and grown to an A^ of 0.5-1.0. Protein expression was then induced by the addition of IPTG at 1 mM final concentration. Cells were grown for 15-19 h post-induction, and harvested by centrifugation at 4230 g for 15 min at 4°C. Cell pastes were washed in 0.1 M Tris, pH 7.4, and frozen at -70°C until purification. The purification scheme of the wild type and mutant FKBP12 includes DEAE, gel exclusion and hydrophobic interaction chromatography, and has been described in detail elsewhere (Park et al, 1992) . Overall yields from the purification scheme were s=50% for all FKBP12 mutants described.
Kinetic and binding equilibria methods
Measurement of the catalytic efficiency {k^lK^ for the PPIase reaction was performed essentially according to Harrison and Stein (1990a) , with the modifications described previously (Park et al, 1992) . The substrate used for the determination of k c JK m and the inhibition constant (K,) was Suc-Ala-LeuPro-Phe-pNA. k^f/Km and K-, values were measured at enzyme concentrations such that k^ was at least 5-fold higher than non-em-Stock solutions of FK506 and rapamycin were prepared in Me 2 SO. The final Me 2 SO concentration in the PPIase assay was 0.5% (v/v). Reactions were initiated with chymotrypsin at a final concentration of 50 Hg/ml for assays at 15°C or 1 mg/ml for reactions at 5°C. Absorbance at 400 nm was monitored at 1 s intervals on a Hewlett-Packard 8452A spectrophotometer with a thermostatted cuvette holder, interfaced to a Model 300 Hewlett-Packard computer. Separate A^, and K m values were determined using the modified coupled chymotrypsin assay devised by Kofron et al. (1991) . Tetrapeptide substrates were dissolved at 150-225 mM in anhydrous trifluoroethanol (TFE)/470 mM LiCl. For a 1 ml reaction volume, 6 mg chymotrypsin were added. To initiate the reaction, substrate solutions and additional TFE were added to bring the final cosolvent concentration to a constant value > n ^ PPIase reaction and drug affinities of FKBPI2 mutants were determined with Sue-Ala-Leu-Pro-Ptie-pNA as substrate at 15°C. These data for wild-type FKBP12 and the D37V mutants were reported previously in Aldape et al. (1992) , and for the H87L and I90A mutants in Futer et al. (1995) . ''Since the F99L mutant was a poor catalyst of the PPIase reaction (0.2% of wild type), ligand affinities (A^j) were determined by fluorescence titration at 15°C using 203 nM injections of FK506 into a 920 nM solution of protein.
of 2.5% (v/v). Assays were performed at 5°C to minimize the non-enzymatic PPIase rate. Reactions were monitored at one of several wavelengths, depending on the concentration of the peptide substrate and p-nitroaniline (pNA) product. The wavelengths used (and corresponding £", values) were 444 (1250), 450 (760), 454 (530) and 460 nm (300). Substrate specificities of the mutants were determined using Suc-AlaPi-Phe-pNA as the substrate, where P ( is Leu, Phe, Val, Ala, Lys or Gly.
The dissociation constants of the F99L mutant for ligands were determined by fluorescence titration. The measurement of fluorescence spectra was performed on a Perkin-Elmer LS-50 instrument using FLDM software running on an IBM PC-XT. The excitation wavelength was 290 nm (5 nm slit width) and emission scans were obtained over the wavelength range 300-380 nm (15 nm slit width). Samples were equilibrated to 5°C prior to collecting the spectra. 1.0 |il injections of a 0.6 mM solution of FK506 or rapamycin in ME2SO were made into 3 ml of a 0.9 |lM mutant FKBP12 solution in 0.1 M Tris, pH 7.8, at 15°C. Five scans were collected and averaged for each sample (Figure 3 ). Scans were corrected for the minor emission of the peptide by subtracting averaged scans of the peptide in buffer at an equivalent concentration to that used in the titration of FKBP12.
Data analysis
For the standard coupled PPIase assay, absorbance data points were fitted to a first-order function using Hewlett-Packard data analysis software for the calculation of /: ca /A' m . K, values were calculated using non-linear fitting to a competitive tight binding equation (Morrison, 1969) employing KineTic software v 3.0 (BioKin Ltd) running on a Macintosh Hex. Separate £ cal and K m parameters were calculated by fitting progress curves to an integrated rate equation derived by Kofron et al (1991) using the KineTic software package running on a Macintosh Hex. The integrated rate equation includes terms for both the catalyzed and uncatalyzed isomerization rates. Initial reaction velocities calculated by this program were then used to calculate k cM and K m .
The fluorescence titration data were analyzed by fitting to a Scatchard equation using MultiFit software (Day Computing) running on a Macintosh Hex. The fractional change in fluorescence intensity at 340 nm was used to solve iteratively for the free drug concentration at each injection point as a function of X t , Af, and K a (the association constant). These data were then fitted to a non-linear least squares fit utilizing a Marquardt algorithm (Connelly et al, 1994) .
Results
FK506 and rapamycin binding
Site-directed mutagenesis was used to make conservative mutations of the FKBP12 internal residues that contact FK506 through hydrophobic and hydrogen bonding interactions ( Figure 2A and Table I ). The indole ring of Trp59 FKBP12 is buried by the pipicolinyl ring of FK506 or rapamycin in the respective complexes (Van Duyne et al, 1993; Wilson et al, 1995) . The mutation of Trp59 to either Leu or Ala results in a 10-to 100-fold decrease in affinity for FK506 and rapamycin compared with wild-type FKBP12 (Table IT) . Phe99 is a central residue at the base of the binding pocket, interacting with the aromatic residues Phe36, Tyr26 and Trp59, as well as the FK506 pipicolinyl ring (Figure 2A and Table I ). It has also been reported to form an unusual type of hydrogen bonding interaction from the side-chain Cj-H to the FK506 C9 keto oxygen atom (Van Duyne et al, 1991 , 1993  Figure 2A ). Such C aTOm -H---O interactions have been observed in many proteins (Burley and Petsko, 1988) and are believed to be energetically favorable, although not to the same degree as a typical hydrogen bond (Thomas et al, 1982 ). An F99L mutation yields a protein with a 20-to 30-fold lower affinity for FK506 and rapamycin than the parent protein. Because of the low enzymatic activity of this mutant, the binding affinities (K4) of the macrolide ligands were determined by fluorescence titration (Figure 3 ).
Tyr26 forms a hydrogen bond to Asp37, as well as the unusual side-chain C5-H hydrogen bond to the FK506 C9 keto oxygen atom. The mutation of Tyr26 to Phe decreases the affinity for FK506 and rapamycin by 37-and 17-fold, respectively. Tyr82 forms a hydrogen bond with the FK506 C8 amide oxygen via the phenol proton. However, the mutation of Tyr82 does not affect FK506 or rapamycin affinity. His87 stacks against Tyr82, and contacts the FK506 or rapamycin C10-C14 pyran ring and the Cll methyl group. The mutation of His87 to Leu lowers the affinity for FK506 and rapamycin 40-and 77-fold, respectively (Futer et al, 1995) . Only minor effects on FK506 or rapamycin binding are seen in the Y80F mutant, which is not in contact with the ligands.
Phe36 also forms a weak hydrogen bond to the C9 keto oxygen atom of FK506 via the aromatic Cg-H. This mutant would no longer be able to form this hydrogen bond, yet the K, values of the F36L mutant for FK506 and rapamycin are unchanged compared with wild-type FKBP12. The mutation of Phe46 or Phe48, residues which do not form hydrogen bonding interactions with FK506, decreases drug-binding affinity by 2-and 7-fold, respectively. Phe46 does make extensive Van der Waals interactions with the pipicolinyl ring of FK506.
Asp37 is a hydrogen bond acceptor for the Tyr26 phenol proton and for the FK506 C10 ketal hydroxyl proton. In the FK506 and rapamycin complexes, Asp37 also forms an electrostatic bond to Arg42 via the guanidino nitrogen proton. The D37V mutant has an affinity for FK506 and rapamycin that is 580-and 180-fold lower, respectively, than the wildtype protein (Aldape et al, 1992) . This is the most dramatic change that we have observed in drug affinity caused by a point mutation. Mutations at position Ile90 of FKBP12 have minimal effects on ligand binding. I90A FKBP12 has K, values for FK506 and rapamycin of 0.25 and 0.70, respectively (Futer et al, 1995) . These K, values are comparable with those of wild-type FKBP12 (K, = 0.6 nM for FK506 and 0.2 nM for rapamycin).
PPIase catalysis
All FKBP12 mutants characterized are active catalysts of the PPIase reaction. Specific activities of FKBP12 variants range from 0.2 to 175.0% of the wild-type protein. However, whereas most mutations have minor effects on catalytic efficiency, mutations at four residues in the active site cause >2-fold decreases in the second-order rate constant (k^/Km) for this reaction. Mutations at two hydrophobic FKBP12 residues at the base of the active site cause the most significant decrease in catalytic efficiency observed (Figure 4) . The mutation of Trp59 to Leu or Ala decreases catalytic efficiency to 13 and 3% of the wild-type activity, respectively. The mutation of Phe99 to Leu decreases the catalytic efficiency to 0.2% of the wild-type activity. Mutations at the other hydrophobic binding pocket residues (Phe36, Phe46 or Phe48 to Leu) result in FKBP12 variants with PPIase specific activities very similar to the wild-type enzyme.
The effects of mutating the FKBP12 Tyr residues 26 and 82 are of interest because these residues both interact with FK506 (Table I) . It has been proposed that hydrogen bonding interactions of substrate with these residues may play an important role in catalysis (vide infra). However, mutating either or both of these residues to Phe generates catalytically active variants (Figure 4) , suggesting that hydrogen bonding interactions with these residues are not essential for substrate binding or catalysis. In contrast, two hydrophilic residues at the solvent-exposed interface of the binding pocket, Asp37 and Arg42, which form hydrogen bonding interactions with ligands, were altered in previous investigations (Aldape et al, 1992; Futer et al, 1995) , and these mutations were observed to cause significant decreases in PPIase activity. Fischer et al. (1993) . Hydrophobic pocket-forming residues predicted for the substrate P, side chain are Phe36, Tyr82, His87, Ile90, Ile91, Ile97 and Phe99. Trp59 interacts with the substrate Phe residue.
•"Comparison of the results for FKBP12 residues that interact with tetrapeptide PPIase substrates, predicted from the MD simulations of the FKBPI2-catalyzed PPIase reaction reported by Orozco et al. (1993) . In general, there are few similarities in the specific hydrogen bonding interactions seen in the two simulations ( Figure 2B) . Tischer et al. (1993) observed a direct hydrogen bonding interaction with the backbone carbonyl of the P2' residue to the Tyr82 OH in their simulation. However, Orozco et al. (1993) suggested that this residue forms either a direct or water-mediated hydrogen bond with the substrate P, carbonyl group.
Substrate specificity profiles for tetrapeptides varying at the Pi position were determined for each of the FKBP12 mutants by measuring kcJK m . The observed relative substrate specificity for each mutant was usually very similar to that observed for wild-type enzyme. The Y82F and H87L mutants are exceptions. These display a lower relative catalytic efficiency than the wild-type protein for the P, = Phe tetrapeptide substrate ( Figure 4 ) and a higher catalytic efficiency for Pi = Lys than the wild-type FKBP12. This altered substrate specificity was also observed for a Y26F/Y82F double mutant. A more detailed kinetic analysis of PPIase catalysis by the Y82F and Y26F/Y82F mutants was thus undertaken.
Separation of the second-order rate constant into individual K m and k^ constants for the cis-trans reaction was accomplished using a modified PPIase assay at a lower temperature (5°C; Kofron et al, 1991; Park et al, 1992) . At this temperature, the ratio of the cis.trans form of the substrate is shifted in the as direction. This analysis (Table IV) revealed that neither the Y82F nor the Y26F/Y82F mutations substantially alter the K m value for FKBP12-catalyzed isomerization of the Pi = Leu, Phe or Gly substrates, suggesting that the binding of the cis substrate to the protein is unaffected. As we have reported previously (Park et al, 1992) , the substrate specificity of FKBP12 catalytic efficiency is predominantly due to a kê ffect, which may indicate that a protein-ligand interaction stabilizing the twisted-amide intermediate has been perturbed. The Y82F mutant shows an 8-fold decrease in Jt^, for the Pi = Leu substrate versus the parent protein, a similar Tetrapeptide substrates in the PPlase reaction used are Sue-Ala-P ( -ProPhe-pNA, where P| is Leu, Phe or Gly. 'K m and t^ values were determined at 5°C by a modified PPlase assay using the solvent-perturbed equilibria method developed by Kofron et al. (1991) with the modifications described previously (Park et al., 1992) . ''Relative k^ (to P| = Leu) in parentheses. C k cu /K m was determined at 5°C by the standard PPlase assay (Aldape et al., 1992; Park el al., 1992) . discrimination in k cal between the P, = Leu versus Phe substrates, and less discrimination versus the P| = Gly substrate. The Y26F/Y82F double mutant is more discriminating than the wild-type protein with respect to the k cU value for P, = Leu versus Phe, but less discriminating with respect to P, = Gly.
Discussion
Based on an analysis of the magnitude and pH dependence of steady-state kinetic parameters, activation parameters and solvent and deuterium isotope effects, a catalytic mechanism for the PPlase reaction was proposed (Harrison and Stein, 1990b; Park et al, 1992) . We suggested that the selective stabilization of an X-Pro twisted-amide intermediate and desolvation were important rate-accelerating factors in PPlase catalysis, lowering the free energy of activation of formation of this intermediate by 6.6 kcal/mol relative to the uncatalyzed reaction. Although the crystal structure of an FKBP12^>eptide substrate complex has not been reported, the molecular details of the PPlase reaction catalyzed by FKBP12 were subsequently investigated in two independent simulation studies (Fischer etal, 1993; Orozco etai, 1993 ). Fischer etal. (1993 modeled the substrate (Ac-Leu-Pro-Phe-NMe) as a type Via proline turn, assuming that the twisted-amide transition state for the substrate is mimicked by the C9 keto carbonyl of FK506 or rapamycin, and that the other interactions seen with these inhibitors are largely preserved. The adiabatic reaction path for the cis-trans interconversion was then mapped out using a combination of molecular mechanics, ab initio, and continuum dielectric methods. It should be noted that the simulations of Fischer et al. (1993) were performed in the gas phase. As such, they cannot invoke water-mediated hydrogen bonds, which may play an important role in catalysis. Likewise, Orozco et al. (1993) modeled the twisted form of their substrate (Ac-Ala-Ala-Pro-Phe-NMe) on rapamycin, but then carried out extensive solvated molecular dynamics (MD) and free energy perturbation calculations.
These investigators proposed details of potential hydrogen bonding and Van der Waals interactions between FKBP12 and peptidyl-prolyl substrate atoms over the time course of their simulation of the cis-trans isomerization, and predicted how the strength of these interactions change as the peptidyl-prolyl substrate is isomerized (Table III; Figure 2B ). Further, FK506 and rapamycin have been proposed to mimic the twistedamide substrate intermediate (Rosen et al., 1990; Schreiber, 1992) . Careful comparison of the effects of point mutations on /tca/^n, for tetrapeptide substrates with the effects on drugbinding constants can be a useful test of the more detailed PPlase reaction mechanisms and whether the macrolide ligands indeed behave as transition state mimics (Rosen et al., 1990; Schreiber, 1992) .
The structure of the FKBP12-FK506 complex revealed a number of hydrophobic and hydrogen bonding interactions between the protein and ligand (Table I ). The mutation of Trp59 and Phe99 resulted in dramatic decreases in FK506 and rapamycin binding, consistent with the importance of the hydrophobic interactions of these residues with the substrate prolyl moiety observed in the MD simulations of Orozco et al. (1993) . Asp37 hydrogen bonds to the C10 hemiketal hydroxyl group of FK506, and the mutation of this residue to Val also dramatically lowers its affinity for macrolide ligands. The mutation of FKBP12 residue Tyr26 to Phe may maintain the unusual Cg-H hydrogen bond to FK506 (to the C9 keto oxygen atom), but nonetheless results in a 50-fold decrease in K, for FK506. Tyr26 makes a hydrogen bond to Asp37, and the Asp side-chain carboxylate forms a salt bridge to Arg42 as well as a hydrogen bond to the C10 hydroxyl group of FK506. The mutation of Tyr26 to Phe may cause a conformational shift of the Asp37 side chain, disrupting these interactions. However, the mutation of Tyr82, which forms a hydrogen bond to the FK506 C8 amide oxygen, does not affect the K-, value. A thermodynamic study of the FKBP12 Y82F mutant provided evidence that the enthalpy required to displace two solvent molecules hydrogen bonded to the Tyr82 phenol proton largely offsets the free energy of binding of FK506 (Connelly et al., 1994) .
The mutagenesis results reported here demonstrate that the PPlase catalytic efficiency of FKBP12 is remarkably insensitive to mutation in the active site. In fact, every mutant we generated is catalytically active. The mutation of Asp37 decreases the catalytic efficiency 10-fold (Aldape etal, 1992) . However, this mutant is not 'catalytically inactive', as our previously reported data were erroneously characterized (Fischer et al, 1993) . Nonetheless, the significant decrease in catalytic efficiency of the Asp37 mutant may reflect the role of Asp37 in destabilizing the cis form of the substrate by making an unfavorable electrostatic interaction with the substrate P| carbonyl oxygen (Fischer et al, 1993; Orozco et al, 1993) , and in stabilizing the twisted-amide intermediate by forming a hydrogen bond to the substrate P| amide nitrogen.
The mutation of Trp59 to Ala and Phe99 to Leu, residues likely to interact with the substrate prolyl ring, also decreases catalytic efficiency. The mutation of Tyr26 or the other activesite Phe residues has only minor effects on PPlase activity, suggesting that if these residues hydrogen bond to the substrate Pi carbonyl oxygen, as proposed by Fischer et al (1993) , such hydrogen bonds neither significantly destabilize the ground state interaction nor stabilize the twisted-amide intermediate.
In characterizing >20 FKBP12 mutants to date, we have found few variants to display an altered PPlase substrate specificity at P, relative to the parent protein (Aldape et al, 1992; Park et al, 1992) . Exceptions to this are the Y82F and H87L single mutants and a Y26F/Y82F double mutant, in which we observed altered substrate specificity for a series of tetrapeptide substrates (Figure 4 ). These residues form stacking interactions with each other and, along with Phe36, Ue90, Ile91, De97 and Phe99, form the hydrophobic pocket for the substrate P, residue. Tyr82 has been proposed to stabilize the twisted-amide substrate intermediate via a direct hydrogen bond to the P 2 ' carbonyl group (Fischer et al, 1993) or via a water-mediated hydrogen bond to the P] carbonyl oxygen (Orozco era/., 1993) .
Then we determined whether the altered substrate specificities observed for the Y82F mutant and the Y26F/Y82F double mutant were caused by the perturbed binding of the cis substrate (reflected in K^ or of the twisted-amide intermediate (reflected in Jt cat ). A kinetic analysis of the Y82F and Y82F/ Y26F mutants (Table IV) indicated that the altered substrate specificity profiles for these mutants were clearly caused by an effect on k^. K m values were indistinguishable within experimental error, suggesting that the binding of the cis substrate to FKBP12 is unaltered. These observations are in good agreement with the trends in the catalytic parameters reported for an FKBP12 Y82L mutant by Bossard et al. (1994) , who also found no effect on K m and a 50-fold decrease in k^. The observed effect on /fc^, supports a role for these residues in stabilizing the twisted-amide intermediate through interactions with the substrate P, residue. The altered substrate specificity of the Tyr82 and His87 mutants is consistent with the formation of water bridges by these residues to the twisted-amide form of the substrate observed during the simulations of Orozco et al. (1993) . The mutation of Tyr82 to Phe increases the relative k cal for P, = Phe or Gly substrates. The increased discrimination of /^a l for P, = Leu versus Phe in the Y26F/ Y82F double mutant versus Y82F probably reflects the role of Tyr26 in stabilizing the Asp37 side chain, which hydrogen bonds to the backbone amide nitrogen of the P, residue. The hydrogen bonding of the Tyr26 to the substrate P| carbonyl (via the aromatic C-H group) appears to be less important because a Phe26 residue should also be able to form this hydrogen bond.
Therefore, we can conclude that while hydrogen bonding by backbone amide heteroatoms and the Asp37 carboxylate side chain are rate-accelerating factors in PPIase catalysis by FKBP12, hydrogen bonding by Tyr26, Phe36 or Phe99 does not contribute significant stabilization energy to the twistedamide intermediate relative to the cis peptide substrate. Instead, these data provide additional evidence that the catalysis of the PPIase reaction proceeds primarily by desolvation and destabilization of the ground state, and by stabilization of the intermediate, primarily through Van der Waals interactions with residues such as Trp59 and Phe99. Such interactions are also the major contributors to the binding energy of FKBP12 complexes for FK506 and rapamycin. Further, the differential effects of these binding pocket mutations on catalytic efficiency versus macrolide-binding affinity lend support to the suggestion (Park et al, 1992; Orozco et al, 1993 ) that FK506 and rapamycin should not be considered as exact 'twisted-amide surrogates', as has been proposed by Rosen et al. (1990) . The characterization of the critical FKBP12-macrolide interactions by mutagenic analysis, together with the structural characterization of the FKBP12-FK506-calcineurin complex (Griffith et al, 1995) and structure-activity of FKBP12-binding compounds (Armistead et al, 1995) , should facilitate the design of novel FKBP12-binding immunosuppressive compounds.
